Reported Friday, Citius Pharmaceuticals FY24 EPS $(5.97) Down From $(5.57) YoY; Cash $3.3M
Reported Friday, Citius Pharmaceuticals FY24 EPS $(5.97) Down From $(5.57) YoY; Cash $3.3M
Net loss was $39.4 million, or ($5.97) per share for the year ended September 30, 2024, compared to a net loss of $32.5 million, or ($5.57) per share for the year ended September 30, 2023, as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense.
截至2024年9月30日，净亏损为3940万美元，折合每股（$5.97），相比于截至2023年9月30日的净亏损3250万美元，折合每股（$5.57），已根据反向股票拆分进行了调整。净亏损的增加反映了运营费用的增加为530万美元，其他收入减少160万美元的影响。运营费用的增加是由于基于股票的补偿和一般及管理费用的增加，而研发费用的减少则抵消了一部分影响。
As of September 30, 2024, the Company had $3.3 million in cash and cash equivalents.
截至2024年9月30日，公司拥有现金及现金等价物330万美元。